Personal information

United States

Activities

Employment (3)

Blueprint Medicines: Cambridge, MA, US

2021-04-26 to present | Principle Scientist (Translational Medicines)
Employment
Source: Self-asserted source
Guang Yang

Dana-Farber Cancer Institute: Boston, MA, US

2018-06-01 to 2021-04-15 | Senior Scientist (Medical Oncology)
Employment
Source: Self-asserted source
Guang Yang

Dana Farber Cancer Institute: Boston, MA, US

2013-06-01 to 2018-05-31 | Instructor in Medicine (Medical Oncology)
Employment
Source: Self-asserted source
Guang Yang

Professional activities (1)

American Society of Hematology: Washington, DC, US

2005-09-01 to present
Membership
Source: Self-asserted source
Guang Yang

Works (29)

The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma

Leukemia
2024-07 | Journal article
Contributors: Hildo C. Lantermans; Fangxue Ma; Annemieke Kuil; Sanne van Kesteren; Sevtap Yasinoglu; Guang Yang; Sara J. Buhrlage; Jinhua Wang; Nathanael S. Gray; Marie José Kersten et al.
Source: check_circle
Crossref

The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance

Blood
2021-11-18 | Journal article
Contributors: Guang Yang; Jinhua Wang; Li Tan; Manit Munshi; Xia Liu; Amanda Kofides; Jiaji G. Chen; Nicholas Tsakmaklis; Maria G. Demos; Maria Luisa Guerrera et al.
Source: check_circle
Crossref

Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia

Journal of Clinical Oncology
2021-02-20 | Journal article
Contributors: Steven P. Treon; Kirsten Meid; Joshua Gustine; Guang Yang; Lian Xu; Xia Liu; Christopher J. Patterson; Zachary R. Hunter; Andrew R. Branagan; Jacob P. Laubach et al.
Source: check_circle
Crossref

Epigenetic Targeting of Waldenström Macroglobulinemia Cells with Bet Inhibitors Synergizes with BCl2 or Histone Deacetylase Inhibition

Epigenomics
2021-01 | Journal article
Contributors: Stephan J Matissek; Weiguo Han; Mona Karbalivand; Mohamed Sayed; Brendan M Reilly; Shayna Mallat; Shimaa M Ghazal; Manit Munshi; Guang Yang; Steven P Treon et al.
Source: check_circle
Crossref

Genomic evolution of ibrutinib‐resistant clones in Waldenström macroglobulinaemia

British Journal of Haematology
2020-06 | Journal article
Contributors: Cristina Jiménez; Gloria G. Chan; Lian Xu; Nickolas Tsakmaklis; Amanda Kofides; Maria G. Demos; Jiaji Chen; Xia Liu; Manit Munshi; Guang Yang et al.
Source: check_circle
Crossref

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.

Blood
2020-04-17 | Journal article
Source: Self-asserted source
Guang Yang
grade
Preferred source (of 2)‎

SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.

Blood cancer journal
2020-01-31 | Journal article
Source: Self-asserted source
Guang Yang

Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas.

Blood advances
2020-01-01 | Journal article
Source: Self-asserted source
Guang Yang

Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.

Blood
2018-12-13 | Journal article
Source: Self-asserted source
Guang Yang

A Novel HCK Inhibitor Kin-8193 Blocks BTK Activity in BTK Cys481 Mutated Ibrutinib Resistant B-Cell Lymphomas Driven by Mutated MYD88

60th ASH Annual Meeting & Exposition
2018-11-29 | Conference paper
Source: Self-asserted source
Guang Yang

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2018-07-25 | Journal article
Source: Self-asserted source
Guang Yang

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.

Blood
2018-03-01 | Journal article
Source: Self-asserted source
Guang Yang

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.

Cell chemical biology
2017-11-09 | Journal article
Source: Self-asserted source
Guang Yang

Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.

Expert review of hematology
2017-06-28 | Journal article
Source: Self-asserted source
Guang Yang

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.

Blood
2017-02-24 | Journal article
Source: Self-asserted source
Guang Yang

Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2017-02-13 | Journal article
Source: Self-asserted source
Guang Yang

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.

Blood
2016-05-03 | Journal article
Source: Self-asserted source
Guang Yang

Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia.

British journal of haematology
2016-04-13 | Journal article
Source: Self-asserted source
Guang Yang

Ibrutinib in previously treated Waldenström's macroglobulinemia.

The New England journal of medicine
2015-04-01 | Journal article
Source: Self-asserted source
Guang Yang

The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells.

British journal of haematology
2015-01-12 | Journal article
Source: Self-asserted source
Guang Yang

Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma.

ACS chemical biology
2014-03-17 | Journal article
Source: Self-asserted source
Guang Yang

Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.

Blood
2014-02-19 | Journal article
Source: Self-asserted source
Guang Yang

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

Blood
2013-07-08 | Journal article
Source: Self-asserted source
Guang Yang

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

The New England journal of medicine
2012-08-01 | Journal article
Source: Self-asserted source
Guang Yang

Inhibition of PAX3 by TGF-beta modulates melanocyte viability.

Molecular cell
2008-11-01 | Journal article
Source: Self-asserted source
Guang Yang

Regulated Fox-2 isoform expression mediates protein 4.1R splicing during erythroid differentiation.

Blood
2007-08-22 | Journal article
Source: Self-asserted source
Guang Yang

An erythroid differentiation-specific splicing switch in protein 4.1R mediated by the interaction of SF2/ASF with an exonic splicing enhancer.

Blood
2004-11-02 | Journal article
Source: Self-asserted source
Guang Yang

High Expression in CHO Cells and Activity of an Anti-P185(erbB2) Mouse/human Chimeric Antibody.

Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica
2001-01-01 | Journal article
Source: Self-asserted source
Guang Yang

List of all peer reviewed articles on Pubmed

Journal article
Source: Self-asserted source
Guang Yang